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Abstract. Antimalarial drug treatment policy in sub-Saharan Africa is generally guided by the results of clinical drug
efficacy studies in patients with uncomplicated Plasmodium falciparum malaria. The selection criteria used to enroll
these patients often vary and may have a significant impact on treatment outcomes. In Kampala, Uganda, we investi-
gated the impact of age, baseline temperature, and pre-treatment parasite density on estimates of treatment efficacy
using a statistical modeling approach in 2,138 patients enrolled in six clinical trials involving seven different treatment
regimens. Decreasing age, increasing temperature, and increasing parasite density were all independent predictors of an
increased risk of treatment failure across all treatment groups. Compared with an unrestrictive approach to subject
selection, enrolling only patients fulfilling selection criteria recommended by the World Health Organization (age < 5
years old, documented fever, and parasite density < 200,000/L) increased the risk of treatment failure by 25−60% for
the different treatment regimens. Caution should be taken when comparing results from drug efficacy studies with
different subject selection criteria.
INTRODUCTION
The emergence of antimalarial drug resistance has forced
many countries in sub-Saharan Africa to review their national
treatment policies. Accurate data on the degree and distribu-
tion of drug resistance are essential for the formulation of
rational drug policies. Typically, drug efficacy data are gen-
erated from in vivo studies assessing the therapeutic response
to antimalarial therapy in patients with symptomatic uncom-
plicated malaria. The World Health Organization (WHO) has
provided standardized guidelines for the assessment and
monitoring of antimalarial drug efficacy with the aim of sup-
porting programmatic decision-making. These protocols have
been designed to collect minimal essential information among
populations at greatest risk and have been widely adopted.1
In areas of high transmission, the WHO guidelines recom-
mend studying patients less than five years of age with a
documented fever and a parasite density between 2000 and
200,000/L at enrollment.
Response to antimalarial therapy may be influenced by
host and parasite factors and can vary with the population
studied. The criteria used to select subjects for an antimalarial
drug efficacy trial defines the study population and can im-
pact on treatment outcome and study results. For example, in
endemic areas, increasing age is associated with greater anti-
malarial immunity and improved therapeutic response,2,3 and
a higher parasite burden at the time of treatment may be
associated with less favorable outcomes.4 The recommended
WHO patient selection criteria are restrictive, and do not
cover the full range of patients with uncomplicated malaria.
In practice, the criteria used to enroll patients into antima-
larial drug efficacy studies often vary with respect to age,
parasite density, and baseline temperature.5
Since 1998, our group has conducted six antimalarial drug
efficacy studies involving seven different treatment regimens
in Kampala, Uganda. These studies have used similar proto-
cols in a common target population with a relatively unre-
stricted approach to patient enrollment. To investigate the
impact of subject selection criteria on treatment outcome, we
evaluated independent predictors of treatment failure and es-
timated the effect that common variations in selection criteria
had on the results obtained in our studies.
MATERIALS AND METHODS
Study site. All studies were conducted between August
1998 and June 2003 at the outpatient department of Mulago
Hospital in Kampala, Uganda. Mulago Hospital is a tertiary
referral hospital that principally serves a poor urban popula-
tion. Malaria is mesoendemic in Kampala, with transmission
peaking after each of two rainy seasons (Ugandan Ministry of
Health, unpublished data).
Patients included in this analysis came from six previously
published clinical trials. The treatment arms and study dates
are as follows: study 1: chloroquine (CQ), August 1998 to
March 1999;3 study 2: CQ versus sulfadoxine-pyrimethamine
(SP), March 1999 to August 1999;6 study 3: SP versus amo-
diaquine (AQ) versus SP plus AQ (SP + AQ), September
1999 to July 2000;7 study 4: SP versus SP + AQ versus SP plus
artesunate (SP + AS), July 2000 to August 2001;8 study 5: SP
versus SP + AQ versus SP plus CQ (SP + CQ), March 2001 to
January 2002;9 and study 6: SP + CQ versus SP + AQ versus
AQ plus AS (AQ + AS), October 2002 to June 2003.10
Informed consent was obtained from all adult participants
and from parents or legal guardians of minors. All protocols
were reviewed and approved by the Institutional Review
Boards of Makerere University, Kampala and the University
of California, San Francisco. In addition, studies 4−6 were
approved by the Ugandan National Council for Science and
Technology, and study 6 was approved by the International
Clinical Studies Review Committee at the National Institutes
of Health.
Subject selection. The protocols used for all of the studies
were similar, and detailed methods have been published pre-
viously as referenced earlier. Briefly, in all studies with the
exception of study 4, subjects were recruited from the popu-
lation of patients presenting to the Mulago Hospital outpa-
tient department with symptoms suggestive of malaria and a
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positive screening blood smear (10% Leishman’s stain for 10
minutes). In study 4, a cohort of healthy children was re-
cruited from the surrounding community and followed for
one year; each time a participant presented with a new epi-
sode of fever a screening blood smear was performed. All
subjects included in the analysis of our six studies fulfilled the
following selection criteria: 1) age  6 months, 2) tympanic
temperature  38°C (equivalent to axillary temperature of
37.5°C) or a history of fever in the previous 48 hours, 3)
absence of severe malaria11 or danger signs (inability to stand
or drink, lethargy, recent convulsions, persistent vomiting), 4)
willingness to provide informed consent, 5) residence within
Kampala 6) Plasmodium falciparum monoinfection, and 7)
parasite density  2,000 asexual parasites/L. Additional re-
strictions to subject selection were used as follows. In study 4,
the upper limit for age was 6 years. In study 6, the upper limit
of age was 10 years, and a provision to exclude patients with
a parasite density  200,000 asexual parasites/L was added
after 14% of the patients were recruited into the trial.
Baseline evaluation and treatment. In all studies, baseline
temperatures were measured using an electronic tympanic
thermometer and blood was removed either by venipuncture
or finger prick for thin and thick smear preparation. Thick
and thin blood smears were stained using 2% Giemsa for 30
minutes. Parasite density was calculated by counting the num-
ber of asexual parasites per 200 white blood cells from the
thick blood smear with the assumption of a white blood cell
count of 8,000/L.
All study drugs were obtained from reputable pharmaceu-
tical companies and medications were dosed according to
modified weight-based guidelines from the WHO for admin-
istration of fractions of tablets.12 All therapy was directly
observed. Patients were observed for 30 minutes after admin-
istration of medication, and the dose was repeated if vomiting
occurred.
Patient follow-up and outcome classification. In all studies
clinical outcome was assessed after 14 days using the WHO
clinical classification system (adequate clinical response
[ACR], early treatment failure [ETF], or late treatment fail-
ure [LTF])12 with the modification that after day 3, patients
with parasitemia and a history of recent undocumented fever
were considered LTF. For the SP arm of study 2 and all
patients in studies 4 and 6, outcomes were assessed after 28
days with genotyping used to distinguish recrudescence from
new infections. Genotyping was successful in 97% of the
samples analyzed. The few samples (n 10) with unsuccess-
ful genotyping were classified as due to recrudescence. With
28-day follow-up, outcomes were reclassified as failures if re-
peat therapy was due to recrudescent parasites and not a
failure if repeat therapy was due to new infections, as previ-
ously described.13 Progression to complicated malaria was de-
fined as treatment failure accompanied by criteria for severe
malaria14 or danger signs12 and referral to the hospital for
intravenous quinine therapy.
In all studies, outcomes were not classified if any of the
following occurred: 1) development of an alternative febrile
illness that would interfere with outcome classification, 2) loss
to follow-up, 3) self-medication with antimalarial drugs, 4)
development of severe malaria or danger signs on day 0 after
leaving the clinic, and 5) withdrawal of informed consent.
Statistical analysis. Data from each study had previously
been entered and verified with Epi-Info version 6.04 (Centers
for Disease Control and Prevention, Atlanta GA). We cre-
ated a pooled database using SPSS version 10 (SPSS Inc.,
Chicago IL). Information extracted from the original patient
data included age, treatment group, baseline temperature,
pre-treatment parasite density, the day repeat therapy was
given, whether repeat therapy was due to recrudescence or
new infection, and whether the patient progressed to compli-
cated malaria (severe malaria or danger signs) after Day 0.
Analysis was done on STATA statistical software version 8.0
(STATA Corporation, College Station, TX) and R statistical
software (R Foundation, Free Software Foundation, Boston,
MA).
Comparisons of baseline characteristics among the differ-
ent treatment groups and identification of independent pre-
dictors of progression to complicated malaria were made us-
ing generalized estimating equations with exchangeable cor-
relation and robust standard errors.15 In our analysis of
predictors of treatment failure, failure was defined as all early
treatment failures and any late treatment failure in studies
with 14-day follow-up and any late treatment failure due to
recrudescence in studies with 28-day follow-up. Predictor
variables included age, baseline temperature, and baseline
parasite density normalized by natural log transformation.
We used an exploratory form of discrete survival analysis to
model the time until treatment failure for these data. Specifi-
cally, we categorized time to failure into five blocks (0–3, 4−7,
8−14, 15−21, and 22−28 days). We then defined the outcome
for each of these blocks to be either 1 (failure) or 0 (not failed
yet). Patients were right-censored at the last block if they had
not failed therapy. Finally, we fit an exploratory (logistic)
regression model using POLYCLASS,16 which chooses the
best model among a large class of potential models (including
main effects, splines, and multiplicative interactions). This lo-
gistic regression model (which actually models the hazard of
treatment failure at each block) can be used to generate the
cumulative probability of failure for any combination of treat-
ment group and baseline covariates. In this way, we can use
parametric extrapolation to estimate the relative efficacy of
different treatments among different potential populations.
In a related set of analyses, we estimated the relative effi-
cacy of treatment among progressively more restricted popu-
lations, defined first by age, then age and temperature, and
finally by age, temperature, and parasite density. To do so, we
took the resulting POLYCLASS model fit described above
and used it to determine the predicted probability of treat-
ment failure (by the last time block). We then computed the
average of these predicted probabilities among the progres-
sively more restrictive populations, which is the estimate of
the marginal probability of treatment failure for each treat-
ment within the specified population.
RESULTS
Baseline characteristics and treatment outcomes. Baseline
characteristics and treatment outcomes for patients from each
of the seven treatment groups are presented in Table 1.
Among studies with no upper limit for age, approximately
half (51%) of the patients were less than five years old. Geo-
metric mean parasite densities and mean baseline tempera-
tures were equivalent for all the treatment groups with the
exception that the SP + AS group had a higher average para-
site density (P < 0.001) and baseline temperature (P < 0.001).
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An elevated temperature at enrollment ( 38.0°C tympanic)
was documented in 50% of the patients; the remaining pa-
tients had a history of recent fever. Among studies with no
upper limit for parasite density, 27% of the patients had para-
site densities > 100,000 asexual parasites/L and 11% of pa-
tients had parasite densities > 200,000 asexual parasites/L.
The risk of clinical failure increased considerably when fol-
low-up was extended from 14 to 28 days (adjusted by geno-
typing), as previously reported.8
Model for treatment failure. Our final POLYCLASS
model included treatment group effects, baseline variables
(age, temperature, parasite density), and variations by time
block. Decreasing age, increasing temperature, and increasing
parasite density were all independently associated with an
increasing risk of clinical treatment failure across all treat-
ment groups. Figure 1 provides a visual presentation of the
effect of changing the level of each individual predictor vari-
able on the risk of treatment failure relative to a low risk
patient population (age  10 years, baseline temperature 
37.5°C, and pre-treatment parasite density  10,000 asexual
parasites/L).
The modeled risks of treatment failure based on variations
in patient selection criteria across all treatment groups are
presented in Table 2. Restricting enrollment to only children
less than five years of age resulted in an appreciable increase
in estimates of treatment failure risk compared with the en-
rollment of patients with no restrictions on age, temperature,
or parasite density. Further restricting enrollment to only pa-
tients with a documented fever led to even greater estimates
of treatment failure risk. Restricting enrollment to pre-
treatment parasite densities < 200,000/L led to a slight de-
crease in estimates of treatment failure risk. Comparing re-
sults based on patients fulfilling the current WHO protocol
(age less than five years, documented fever, and parasite den-
sity < 200,000/L) to an unrestricted patient population, the
relative risk of treatment failure was 1.25 for the CQ treat-
ment group and ranged from 1.44 to 1.60 in the remaining
treatment groups.
Risk for progression to complicated malaria. A total of 22
of 2,138 patients (1%) treated for uncomplicated malaria pro-
gressed to complicated malaria requiring intravenous quinine
therapy. The risk of progression to complicated malaria was
limited to children less than five years of age (22 of 1,304
versus 0 of 834; P  0.0002) and always occurred within the
first three days of follow-up. Restricting our analysis to chil-
dren less than five years of age, there were no patients who
progressed to complicated malaria receiving artesunate-
containing combination therapy (0 of 232 versus 22 of 1,072;
P 0.03). In a multivariate analysis restricted to children less
than five years of age not receiving artesunate, the only sig-
nificant independent predictor of progression to complicated
malaria was increasing parasite density at enrollment (odds
ratio  3.2 for each log increase in parasite density, 95%
confidence interval  2.1−4.7, P < 0.0001). The risk of pro-
gression to complicated malaria stratified by parasite density
in children less than five years of age not receiving artesunate
is presented in Figure 2. The risk was low (< 1%) for parasite
densities less than 100,000/L, with the greatest interval in-
crease in risk occurring with parasite densities > 500,000/L
compared with parasite densities of 200,000−500,000/L
(23.8% versus 5.9%).
DISCUSSION
Clinical response to antimalarial therapy involves a com-
plex interaction between the parasites, the drugs, and the host
response. In vivo tests are considered the gold standard
method of measuring antimalarial drug resistance.12 These
studies traditionally focus on the interaction between the
parasite and drug; however, host factors may have important
effects on the results of in vivo studies.17,18 For example, a
semi-immune patient might be cured despite being infected
with parasites genetically resistant to the drug given.2 In this
study, we show that age, temperature, and parasite density
are all independent predictors of antimalarial drug efficacy
across a wide range of commonly used treatment regimens.
Identification of such predictor variables can help improve
our understanding of the biologic nature of treatment re-
sponse. In addition, our results show that the selection criteria
used to enroll patients can have a significant impact on esti-
mates of antimalarial drug efficacy.
Host immunity plays a critical role in the clearance of ma-
larial parasites. For example, the ability of monocytes to kill
intracellular parasites is a function of antibody-dependent
mechanisms19 and the production of specific antibodies has
been associated with protection against clinical attacks of ma-
laria.20 Acquired antimalarial immunity develops following
TABLE 1
Baseline patient characteristics and treatment outcomes*
Treatment
group No.
Age (years)
Temperature
°C† Parasite density (asexual parasites/L)
14-Day
clinical
failure‡
28-Day
clinical
failure§
Complicated
malaria¶
no. (%)Median < 5 Range Mean > 38.0°C
Geometric
mean > 100,000 > 200,000 > 500,000
CQ 352 4.0 55% 0.5–60 38.0 48% 35,520 26% 11% 2% 49% NA 9 (3)
SP 549 3.7 63% 0.5–50 37.9 50% 38,940 26% 12% 2% 14% 32% 6 (1)
AQ 131 4.0 53% 0.5–50 38.0 53% 29,970 21% 9% 2% 7% NA 0
SP + CQ 265 5.0 49% 0.5–44 37.8 46% 32,500 23% 5% 1% 8% 36% 2 (1)
SP + AQ 541 4.0 63% 0.5–50 38.0 49% 36,400 26% 9% 1% 2% 8% 5 (1)
SP + AS 181 3.3 91% 0.6–5.7 38.3 66% 61,080 41% 15% 2% 0 17% 0
AQ + AS 119 4.0 56% 0.5–10 38.0 45% 29,890 22% 2% 1% 0 3% 0
Total 2,138 4.0 61% 0.5–60 38.0 50% 37,150 26% 9% 1% – – –
* CQ  chloroquine; NA  not available; SP  sulfadoxine-pyrimethamine; AQ  amodiaquine; AS  artesunate.
† Tympanic temperature.
‡ Proportion of patients with early or late treatment failure according to the World Health Organization classification system.
§ Proportion of patients with early or late treatment failure adjusted for genotyping. Including only those patients enrolled in studies with 28-day follow-up and with successful genotyping.
¶ Progression to severe malaria or danger signs after day 0.
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repeated exposure to infecting parasites. The association be-
tween increasing age and a decreasing risk of treatment fail-
ure has been previously reported in studies of different anti-
malarial treatments conducted in a variety of epidemiologic
settings,2,21–25 and it has been proposed that age is the best
surrogate marker of acquired immunity in endemic areas.2
The impact of acquired immunity on the response to antima-
larial therapy should be independent of the drug-parasite in-
teraction, supported by the consistent association between
age and treatment response across a wide range of antima-
TABLE 2
Estimated risk of 28-day treatment failure based on selection criteria and treatment*
Patient selection criteria
Treatment group
CQ SP AQ SP + CQ SP + AQ SP + AS AQ + AS
All patients 71% 27% 15% 34% 5.8% 13% 2.4%
Age < 5 years 84% 37% 22% 43% 8.1% 17% 3.2%
Age < 5 years, temperature > 38°C 90% 44% 25% 51% 9.6% 21% 4.1%
Age < 5 years, temperature > 38°C, parasite density < 200,000/L† 89% 41% 24% 49% 9.0% 20% 3.8%
* For definitions of abbreviations, see Table 1.
† Patient selection criteria based on the World Health Organization protocol for high transmission areas.
FIGURE 1. Cumulative probability of failure for each treatment group based on combinations of baseline covariates estimated from a
POLYCLASS regression model. Upper left graph displays results of a baseline low risk patient population (age 10 years, baseline temperature
 37.5°C, and pre-treatment parasite density  10,000 asexual parasites/L). Upper right graph demonstrates the independent effects of
decreasing age. Lower left graph demonstrates the independent effects of increasing parasite density. Lower right graph demonstrates the
independent effects of increasing temperature. CQ  chloroquine; SP  sulfadoxine-pyrimethamine; AQ  amodiaquine; AS  artesunate.
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larial treatment regimens observed in this study. The relation-
ship between age and treatment response is likely to vary with
the level of malaria transmission intensity and the rate at
which antimalarial immunity is acquired. In areas of higher
transmission, protective immunity is acquired earlier in life.26
Thus, the age associated with the sharpest decrease in the
rates of antimalarial treatment failure should be inversely
proportional to the level of transmission intensity.
In this study, higher parasitemia at presentation was asso-
ciated with an increased risk of treatment failure across a
wide range of antimalarial treatment regimens. Treatment
with antimalarial drugs will optimally reduce the number of
parasites between 100- and 10,000-fold per asexual cycle.27
Parasite reduction appears to be a first-order process, such
that a fixed fraction of the parasite population is removed
with each successive cycle provided that the minimum para-
siticidal concentration of the drug is exceeded.28 A higher
parasite biomass at the time of treatment initiation has pre-
viously been proposed to increase in the risk of treatment
failure.27 Although precise quantification of parasite biomass
in patients infected with P. falciparum malaria is not possible
due to fluctuations during the parasite life cycle and seques-
tration, peripheral parasitemia has been used as a relative
estimate of the burden of infection. Higher parasitemia at
presentation has been associated with an increased risk of
early and late treatment failure in patients treated with chlo-
roquine24,25,29 and for late treatment failure in patients
treated with artesunate,4 quinine,30 and mefloquine.21 In en-
demic areas, patients with P. falciparum malaria are fre-
quently infected with multiple genetically distinct strains.13
Patients with higher pre-treatment parasitemias may be more
likely to harbor a resistant strain, or to experience the spon-
taneous selection of resistant mutants. Additionally, a higher
pretreatment parasite burden may predispose to recrudes-
cence by simply increasing the probability that a parasite will
survive the effect of short-acting artemisinins, for which para-
site drug resistance has not been reported.4
We observed that increasing baseline temperature was an
independent predictor of treatment failure across all treat-
ment groups. The underlying biologic mechanism for this as-
sociation is unclear. A higher temperature at presentation
may represent a surrogate marker of a less effective host
immune response to infection. We are unaware of previous
studies reporting an independent association between base-
line temperature and treatment failure, which may be due to
a true lack of association, a failure to consider temperature as
a potential predictor variable, or a failure to enroll patients
with a wide range of baseline temperatures as done in this
study. Further studies of the association between temperature
and response to antimalarial therapy are warranted.
Ideally, patients enrolled in studies of treatment of uncom-
plicated malaria should be at low risk for progression to com-
plicated disease requiring hospitalization. In this study, we
found that none of the 834 patients more than five years of
age progressed to complicated disease. Interestingly, none of
the 328 patients treated with an artesunate-containing regi-
men (all  10 years old) developed complicated disease, sug-
gesting that this highly active, rapidly acting drug may protect
against early disease progression. The only predictor of pro-
gression to complicated disease in this study was a higher
pre-treatment parasite density. Among children less than five
years old who did not receive artesunate, the risk was of
progression to complicated disease was only 1% for those
with parasite densities < 200,000/L and 9% for those 
200,000/L, supporting the WHO recommendations of ex-
cluding patients above this threshold.
Attempts have been made to standardize selection criteria
for antimalarial trials from similar epidemiologic settings. The
WHO recommends that in areas of high transmission study
subjects be limited to children less than five years old with a
documented fever and parasite density < 200,000 asexual
parasites/L. However, the selection criteria used in antima-
larial drug efficacy studies from high transmission areas fre-
quently vary. In an extensive review of 108 studies from
highly endemic areas of Africa between 1996 and 2002, 28%
of the studies enrolled patients more than five years of age.5
Similarly, considerable variability existed in criteria for tem-
perature and parasite density. Few of these studies controlled
for these differences in their analyses, making it difficult to
directly compare results and monitor trends in drug resis-
tance. Our analysis shows the practical implications that sub-
ject selection criteria may have on the results of antimalarial
drug efficacy trials. Compared with an unrestrictive approach
(enrolling all patients with uncomplicated malaria), limiting
enrollment to only patients fulfilling selection criteria recom-
mended by the WHO would have led to a 25% increase in the
reported risk failure to CQ and a 44−60% increase in the
reported risk of failure to the other treatment regimens evalu-
ated. An awareness of the effects of age, temperature, and
parasite density is important when comparing studies and
monitoring trends in drug resistance. A standardized ap-
proach to subject selection criteria should be used in studies
from similar epidemiologic settings when possible, or results
should be stratified to allow for direct comparison of similar
patient populations.
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